Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Ravaud

Showing results (421-430 of 457) with videos related to

Pageof 46
Sort By:
Research Integrity and Peer Review|November 7, 2018
Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health dataLinda Kwakkenbos, Edmund Juszczak, Lars G Hemkens, et al.
Circulation|December 10, 2009
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disordersDavid Attias, Chantal Stheneur, Carine Roy, et al.
International Journal of Cardiology|August 28, 2017
Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupusNathalie Morel, Kateri Lévesque, Alice Maltret, et al.
Journal of Clinical Epidemiology|November 25, 2022
Instruments assessing risk of bias of randomized trials frequently included items that are not addressing risk of bias issuesYing Wang, Maryam Ghadimi, Qi Wang, et al.
BMJ Open|August 8, 2018
Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health dataLinda Kwakkenbos, Mahrukh Imran, Kimberly A McCord, et al.
The Cochrane Database of Systematic Reviews|June 1, 2023
Interleukin-6 blocking agents for treating COVID-19: a living systematic reviewLina Ghosn, Rouba Assi, Theodoros Evrenoglou, et al.
Annals of the Rheumatic Diseases|December 25, 2012
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registryJacques-Eric Gottenberg, Gael Cinquetti, Claire Larroche, et al.
Archives of Cardiovascular Diseases|May 31, 2024
Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) studyAlexandre Gautier, Nicolas Danchin, Gregory Ducrocq, et al.
Annals of the Rheumatic Diseases|April 27, 2018
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)Pierre Charles, Benjamin Terrier, Élodie Perrodeau, et al.
BMJ Open|April 30, 2021
Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE)Mahrukh Imran, Linda Kwakkenbos, Stephen J McCall, et al.
Pageof 46

Showing results (421-430 of 457) with videos related to

Sort By:
Pageof 46
Research Integrity and Peer Review|November 7, 2018
Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health dataLinda Kwakkenbos, Edmund Juszczak, Lars G Hemkens, et al.
Circulation|December 10, 2009
Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disordersDavid Attias, Chantal Stheneur, Carine Roy, et al.
International Journal of Cardiology|August 28, 2017
Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupusNathalie Morel, Kateri Lévesque, Alice Maltret, et al.
Journal of Clinical Epidemiology|November 25, 2022
Instruments assessing risk of bias of randomized trials frequently included items that are not addressing risk of bias issuesYing Wang, Maryam Ghadimi, Qi Wang, et al.
BMJ Open|August 8, 2018
Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health dataLinda Kwakkenbos, Mahrukh Imran, Kimberly A McCord, et al.
The Cochrane Database of Systematic Reviews|June 1, 2023
Interleukin-6 blocking agents for treating COVID-19: a living systematic reviewLina Ghosn, Rouba Assi, Theodoros Evrenoglou, et al.
Annals of the Rheumatic Diseases|December 25, 2012
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registryJacques-Eric Gottenberg, Gael Cinquetti, Claire Larroche, et al.
Archives of Cardiovascular Diseases|May 31, 2024
Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) studyAlexandre Gautier, Nicolas Danchin, Gregory Ducrocq, et al.
Annals of the Rheumatic Diseases|April 27, 2018
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)Pierre Charles, Benjamin Terrier, Élodie Perrodeau, et al.
BMJ Open|April 30, 2021
Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE)Mahrukh Imran, Linda Kwakkenbos, Stephen J McCall, et al.
Pageof 46